France: Researchers have found in a new multicenter randomized clinical trial of patients with anterior STEMI that the addition of low-dose rivaroxaban to dual antiplatelet therapy (DAPT) did not ...

Discover how modern cardiovascular services protect your heart. Learn about expert cardiology care teams and preventative ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Anticoagulation is a critical component in the treatment of cardiovascular diseases. Large randomised controlled trials have demonstrated that direct oral anticoagulants (DOACs) are effective and safe ...

New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare New data specific to patients ...